Drugs / GVAX Pancreas Vaccine

Trials 7 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT03161379 Feb 2018 → Feb 2024 malignant pancreatic neoplasm Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Completed No outcome recorded
Phase 2 NCT03006302 Jan 2018 → Aug 2023 pancreatic adenocarcinoma Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Completed No outcome recorded
Phase 2 NCT03190265 Dec 2017 → Aug 2022 malignant pancreatic neoplasm Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Completed No outcome recorded
Phase 2 NCT02004262 Feb 2014 → Jan 2016 Aduro Biotech, Inc. Completed No outcome recorded
Phase 2 NCT01595321 Oct 2012 → Oct 2023 malignant pancreatic neoplasm Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Completed No outcome recorded
Phase 2 NCT01088789 Apr 2010 → Jul 2024 overdue pancreatic adenocarcinoma Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Active not recruiting No outcome recorded
Phase 2 NCT00389610 Sep 2006 → Oct 2021 malignant pancreatic neoplasm Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as GVAX pancreas vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT00389610
6

NCT03006302

NCT01088789

NCT03161379

NCT03190265

NCT02004262

NCT01595321

Modality Vaccine “adjuvant GVAX pancreas vaccineNCT00389610